Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT06129747 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2026-05-07
Summary
The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.
Conditions
- Breast Cancer
- Tumor, Breast
Interventions
- RADIATION
-
Radiation Therapy
Weeks 1, 2 and 3 * Weeks 1, 2 and 3 will include 5 days of treatment. * One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes.
Sponsors & Collaborators
-
Case Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Janice Lyons, MD · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
-
Rahul Tendulkar, MD · Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-30
- Primary Completion
- 2029-08-09
- Completion
- 2029-08-09
Countries
- United States
Study Locations
More Related Trials
-
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
NCT01167192 ·Status: TERMINATED ·Phase: PHASE2
-
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.
NCT06839547 ·Status: NOT_YET_RECRUITING
-
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
NCT03561740 ·Status: RECRUITING ·Phase: PHASE3
-
Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study
NCT06890871 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
NCT03807765 ·Status: COMPLETED ·Phase: PHASE1
-
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
NCT00470847 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT04711824 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
NCT03955640 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
NCT01290718 ·Status: TERMINATED ·Phase: PHASE2
-
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
NCT06492759 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer
NCT03457467 ·Status: UNKNOWN ·Phase: PHASE2
-
Olaparib and Radiotherapy in Inoperable Breast Cancer
NCT02227082 ·Status: COMPLETED ·Phase: PHASE1
-
Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer
NCT01501669 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
NCT00977379 ·Status: TERMINATED ·Phase: PHASE2
-
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT04009044 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
NCT03483012 ·Status: COMPLETED ·Phase: PHASE2
-
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
NCT03691493 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
NCT03542175 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
NCT06134375 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
NCT00097487 ·Status: COMPLETED
-
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
NCT00191451 ·Status: COMPLETED ·Phase: PHASE2
-
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
NCT03066947 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
NCT01289353 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
NCT01615068 ·Status: COMPLETED